Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

• Status: Completed
• Trial end date: 2018-10-26

Summary

Chemotherapy given together is a standard way to treat your cancer. One standard treatment includes a combination of docetaxel, cisplatin, and fluorouracil. However, the original combination of these three drugs can cause many side effects. This study is being done to find out if these three drugs can be given at lower doses more often, with fewer side effects and still maintain the same benefit as the standard way of giving this three drug combination. If your tumor overexpresses a protein called Her2, you are also eligible to receive trastuzumab with chemotherapy. Trastuzumab is a medicine that has been approved by the US Food and Drug Administration for the treatment of Her2 positive breast cancer. Trastuzumab is now also a standard treatment in combination with chemotherapy for the treatment of Her2 positive stomach cancer. If your tumor is Her2 positive, you would receive the modified administration schedule of docetaxel, cisplatin, and fluorouracil with trastuzumab.

• Phase: Phase 2

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: City of Hope National Medical Center; Long Island Jewish Medical Center; Medical College of Wisconsin; Memorial Cancer Institute, Florida; Nebraska Cancer Specialists Methodist Estabrook Cancer Center; Piedmont Hospital Research Institute; Queens Health Network; Roche-Genentech; Roche/Genetech; Sanofi; University of Pittsburgh; Weill Medical College of Cornell University
• Treatments: Cisplatin; Docetaxel; Fluorouracil; Leucovorin; Trastuzumab